Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Daiichi Sankyo to not proceed with lung cancer study

Written by: | no-reply@reuters.com | Dated: Tuesday, May 31st, 2016

Daiichi Sankyo Co Ltd said it will not proceed with the second part of its late-stage study on the lung cancer drug, patritumab.

This decision on Tuesday followed the recommendation of an independent data monitoring committee that concluded the first part of the study did not meet the required efficacy criteria.

However, there were no safety concerns identified by the committee.

 

 

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta)

Source: Reuters Health

http://www.reuters.com/article/us-daiichi-sankyo-study-idUSKCN0YM1K8

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation